Orthofix Medical Inc (NASDAQ:OFIX) insider Kimberley A. Elting sold 7,000 shares of the business’s stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $61.05, for a total transaction of $427,350.00. Following the transaction, the insider now owns 22,740 shares of the company’s stock, valued at $1,388,277. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
OFIX opened at $62.37 on Friday. The firm has a market cap of $1.15 billion, a PE ratio of 33.33, a PEG ratio of 3.59 and a beta of 0.30. Orthofix Medical Inc has a one year low of $50.41 and a one year high of $63.57.
Orthofix Medical (NASDAQ:OFIX) last released its quarterly earnings results on Monday, October 29th. The medical device company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $111.70 million during the quarter, compared to analyst estimates of $110.65 million. Orthofix Medical had a net margin of 1.45% and a return on equity of 10.97%. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.42 EPS. As a group, sell-side analysts anticipate that Orthofix Medical Inc will post 1.75 earnings per share for the current fiscal year.
A number of research analysts have recently commented on OFIX shares. TheStreet upgraded shares of Orthofix Medical from a “c+” rating to a “b-” rating in a research report on Monday, September 10th. BidaskClub lowered shares of Orthofix Medical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 12th. Cantor Fitzgerald boosted their price target on shares of Orthofix Medical to $66.00 and gave the company an “overweight” rating in a research report on Tuesday, August 7th. Finally, Zacks Investment Research lowered shares of Orthofix Medical from a “hold” rating to a “sell” rating in a research report on Thursday, August 9th. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $67.67.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Orthofix Medical Inc (OFIX) Insider Sells 7,000 Shares of Stock” was originally published by WKRB News and is the sole property of of WKRB News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.wkrb13.com/2018/11/09/insider-selling-orthofix-medical-inc-ofix-insider-sells-7000-shares-of-stock.html.
Orthofix Medical Company Profile
Orthofix Medical Inc, a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures.
Further Reading: Growth Stocks
Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.